Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II clinical trial to compare the glycaemic control, safety and tolerability of AT247 with Fiasp® when administered by insulin pump over an extended period

Next Previous
X
Search
Trial Profile

Phase II clinical trial to compare the glycaemic control, safety and tolerability of AT247 with Fiasp® when administered by insulin pump over an extended period

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Arecor

    • Most Recent Events

    • 07 Apr 2021 New trial record
    • 31 Mar 2021 According to an Arecor media release, the company received grant from Innovate UK to support the Phase II development of AT247.
    • 31 Mar 2021 According to an Arecor media release, this trial is expected to commence in H1 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top